Immunocore Holdings plc has reported early clinical activity from what it describes as the first combination of two T-cell engagers to show activity in a solid tumour, pairing its approved gp100-targeted therapy KIMMTRAK, or tebentafusp, with investigational PRAME-targeted brenetafusp in metastatic uveal melanoma. In 17 evaluable HLA-A*02:01-positive patients treated with the combination in the first-line setting, the company reported an estimated two-year overall survival rate of 70%, while median overall survival had not been reached after a median 29 months of follow-up.
The November 6 data, presented from the ongoing Phase 1/2 IMC-F106C-101 programme at the Society for Immunotherapy of Cancer annual meeting, are unusually intriguing because KIMMTRAK already has randomised evidence showing an overall survival benefit in this disease. Immunocore is therefore not attempting to rescue an ineffective backbone. It is asking whether simultaneous T-cell redirection against two different melanoma antigens, gp100 and PRAME, can deepen or prolong the benefit of a medicine that has already established a new treatment standard for eligible patients.
The early results justify testing that hypothesis, but they do not answer it. The first-line efficacy dataset contains only 17 evaluable patients, there is no concurrent KIMMTRAK-only control arm, and the apparent survival figures cannot be compared directly with historical KIMMTRAK trial results. Immunocore is planning the randomised DUET-UVEAL Phase 2/3 study precisely because the next question is not whether the combination can produce responses, but whether brenetafusp adds clinically meaningful benefit to an already effective T-cell engager.
What do the first KIMMTRAK plus brenetafusp results actually show in metastatic uveal melanoma?
At the June 2026 data cut-off, 26 patients with metastatic uveal melanoma had received brenetafusp in combination with tebentafusp, while 22 had received clinically active doses of brenetafusp monotherapy. The most relevant efficacy analysis focused on 17 evaluable first-line patients receiving the combination.
Immunocore reported an objective response rate of 29%, a disease-control rate of 71% and median progression-free survival of 8.1 months. Responses also appeared durable within the limits of the small dataset, with a reported median duration of response of 24.1 months. Ten of the 17 first-line patients remained on study at the data cut-off.
Estimated overall survival was 88% at one year and 70% at two years, while median overall survival had not yet been reached after 29 months of median follow-up. Among 11 patients surviving beyond two years, seven had received only tebentafusp plus brenetafusp rather than additional subsequent anticancer therapy, according to the company.
Those survival numbers are the most attention-grabbing part of the update, but they also require the greatest caution. With only 17 evaluable first-line patients, a few additional deaths or longer follow-up could materially alter the estimated survival curve. The results are therefore best understood as a strong Phase 1 signal supporting randomised development, not evidence that the combination has already improved survival compared with KIMMTRAK alone.
Why is KIMMTRAK such a demanding benchmark for Immunocore’s own combination strategy?
KIMMTRAK is not merely an approved treatment with response-rate data. Its original FDA approval in January 2022 was based on a randomised Phase 3 trial of 378 previously untreated HLA-A*02:01-positive patients with unresectable or metastatic uveal melanoma, where overall survival was the primary endpoint.
Median overall survival in the original analysis was 21.7 months with KIMMTRAK compared with 16.0 months using investigator’s choice of pembrolizumab, ipilimumab or dacarbazine. The hazard ratio was 0.51, establishing a statistically significant survival advantage even though conventional tumour shrinkage was relatively uncommon.
Longer follow-up has reinforced that survival effect. Immunocore reported in 2026 that five-year overall survival was 16% with KIMMTRAK compared with 8% in the original control group, with median overall survival of 21.6 versus 16.9 months and a hazard ratio of 0.67.
That history creates a useful warning when interpreting the new combination. Tebentafusp demonstrated that overall survival in metastatic uveal melanoma does not necessarily track neatly with conventional response rate or progression-free survival. Consequently, the combination’s 29% response rate and 8.1-month median progression-free survival are encouraging, but they cannot substitute for a controlled survival comparison.
For Immunocore, the commercial objective is also unusually demanding. Adding brenetafusp will have to produce enough incremental efficacy to justify greater treatment complexity and the additional adverse-event burden associated with exposing patients to two immune-activating agents rather than one.
Why could targeting both gp100 and PRAME produce a different immune response?
KIMMTRAK and brenetafusp are built on Immunocore’s ImmTAC platform but recognise different tumour-associated antigens. Tebentafusp uses a soluble engineered T-cell receptor to recognise a gp100 peptide presented by HLA-A*02:01 and links that recognition to an anti-CD3 immune-effector domain that recruits T cells to attack the target cell.
Brenetafusp applies the same broad therapeutic concept to PRAME, or preferentially expressed antigen in melanoma. PRAME is expressed across several cancers and has been associated with unfavourable biology in metastatic uveal melanoma, making it an attractive second target for immune redirection.
The combination is intended to attack tumour cells through two distinct antigen-recognition systems rather than increasing the dose of a single T-cell engager. In theory, that could broaden tumour targeting, reduce the ability of heterogeneous tumour populations to escape through insufficient expression of one antigen and increase overall T-cell-mediated pressure on the cancer.
That rationale remains a hypothesis until comparative clinical evidence establishes an incremental patient benefit. Solid tumours can evade immune therapy through mechanisms extending well beyond antigen expression, including changes in antigen presentation, immune-cell exhaustion and suppressive tumour microenvironments. Dual targeting may increase the number of vulnerable cancer cells without necessarily overcoming every form of resistance.
Does the safety profile suggest two T-cell engagers can be combined without excessive immune toxicity?
The preliminary safety dataset provides an important reason Immunocore believes it can move the combination forward. Cytokine release syndrome was the most frequent treatment-related adverse event, occurring in 77% of patients who received the combination and 73% receiving brenetafusp monotherapy.
Most CRS events were Grade 1 or Grade 2. Immunocore reported no Grade 3 or Grade 4 CRS with the combination, while Grade 3 CRS occurred in 5% of patients receiving brenetafusp alone. Grade 3 or Grade 4 treatment-related adverse events occurred in 38% of combination-treated patients and 41% of monotherapy patients, most commonly transient reductions in lymphocyte counts that resolved without intervention.
No treatment-related adverse event resulted in treatment discontinuation or death in either group at the reported cut-off. The company also reported rash as another common effect consistent with the mechanism of these therapies.
These findings are reassuring within an early development programme, but the cohort remains too small to define uncommon risks. KIMMTRAK itself carries a boxed warning for cytokine release syndrome, and its approved label requires patients to be monitored for at least 16 hours after each of the first three infusions. Combining two immune-redirecting agents therefore creates an additional safety question that DUET-UVEAL will need to examine across a much larger population and longer treatment exposure.
The relevant benchmark is not whether manageable CRS is expected mechanistically. It is whether any additional toxicity is proportionate to the incremental clinical benefit delivered by adding brenetafusp.
Why do the molecular-response data strengthen the biological case without proving clinical benefit?
Immunocore also reported circulating tumour DNA results from nine combination-treated patients who were evaluable for molecular response. Eight of the nine, or 89%, demonstrated a molecular response, while four achieved ctDNA clearance.
These findings provide another indication that the combination is exerting biological pressure on the cancer. Reductions in circulating tumour DNA can be useful in understanding treatment activity and may eventually help identify early response patterns.
The analysis remains exploratory and extremely small. Four patients clearing ctDNA does not establish improved progression-free or overall survival, and molecular response cannot substitute for validated clinical outcomes in a disease where the existing standard has already demonstrated a survival advantage.
Its value at this stage is therefore mechanistic. The ctDNA results support the argument that dual antigen targeting is doing more than producing transient radiographic changes, but DUET-UVEAL will still need conventional clinical endpoints to establish whether the biological effect changes patient outcomes.
How different is the brenetafusp monotherapy signal from the first-line combination result?
The same Phase 1/2 programme included 16 evaluable patients receiving brenetafusp monotherapy in the second-line or later setting. Immunocore reported a 19% objective response rate, a median duration of response of 14.5 months, a disease-control rate of 63% and median progression-free survival of 4.2 months.
Median overall survival in that group was 20.3 months, with one-year and two-year survival rates of 63% and 31%, respectively. Those numbers establish that brenetafusp has independent antitumour activity in metastatic uveal melanoma rather than functioning only as a companion to tebentafusp.
They cannot be used to calculate the incremental value of the combination because the monotherapy population was treated later in the disease course. Patients receiving second-line or later therapy are clinically different from previously untreated patients, and comparing the two cohorts directly would confound treatment effect with treatment-line and baseline-risk differences.
The monotherapy activity nevertheless strengthens Immunocore’s rationale for combining the two medicines. A second T-cell engager with demonstrable independent activity is a more credible combination partner than an agent whose contribution cannot be separated from the established backbone.
Why is DUET-UVEAL the trial that will determine whether the 70% survival signal matters?
Immunocore plans to initiate DUET-UVEAL as a randomised Phase 2/3 study in HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. The planned design will provide the controlled evidence missing from the current Phase 1/2 dataset.
The central question is straightforward: does adding brenetafusp to tebentafusp improve outcomes enough to justify dual treatment compared with the current KIMMTRAK-based standard? Because tebentafusp already has proven survival benefit, the control arm and endpoint strategy will be particularly important.
Randomisation should reduce the risk that the striking early survival result reflects patient selection, small sample size or other baseline differences rather than the second drug. It will also provide a far better estimate of the combination’s safety profile, treatment discontinuation rate and durability.
A successful Phase 2/3 programme could also establish a precedent extending beyond uveal melanoma. T-cell engager combinations have become familiar in haematological malignancies, but combining two separate TCR-based engagers against different antigens in a solid tumour remains largely unexplored clinically.
If the strategy works, Immunocore could gain evidence supporting a broader concept of multi-antigen T-cell redirection rather than simply producing another combination regimen in one rare cancer.
Could brenetafusp become more valuable outside uveal melanoma than inside it?
Brenetafusp is already being developed beyond the combination with KIMMTRAK. Immunocore is running the Phase 3 PRISM-MEL-301 trial in first-line advanced or metastatic cutaneous melanoma, where HLA-A*02:01-positive patients are randomised to brenetafusp plus nivolumab or a control regimen of nivolumab or nivolumab plus relatlimab.
That programme potentially addresses a much larger patient population than metastatic uveal melanoma. The primary endpoint is blinded independent central review progression-free survival, with overall survival and response rate among the secondary endpoints.
PRAME is also expressed in multiple other tumour types, giving Immunocore a broader development rationale for the antigen if clinical activity proves reproducible. The current metastatic uveal melanoma data are valuable partly because they provide another human validation signal for brenetafusp while the larger cutaneous melanoma Phase 3 programme continues.
Success in DUET-UVEAL and PRISM-MEL-301 would therefore answer different questions. One would establish whether brenetafusp can improve an already proven T-cell engager backbone in a rare cancer. The other would test whether a PRAME-targeted ImmTAC can compete in the much broader checkpoint-inhibitor landscape of cutaneous melanoma.
What does the SITC update mean for Immunocore’s commercial KIMMTRAK franchise?
KIMMTRAK remains Immunocore’s only marketed product and generated $102.2 million in net revenue during the third quarter of 2026. Net revenue reached $324.8 million for the first nine months of the year, up 10% year over year.
The drug is approved in 39 countries and has been launched in more than 30. Immunocore is also attempting to expand its commercial opportunity beyond the current metastatic uveal melanoma indication through late-stage development in previously treated advanced cutaneous melanoma and through other lifecycle programmes.
Adding brenetafusp could provide another way to extend the uveal melanoma franchise without replacing KIMMTRAK. Instead of cannibalising the existing product, a successful dual regimen would potentially increase the therapeutic value built around tebentafusp and reinforce Immunocore’s position in a disease where it already controls the only FDA-approved systemic therapy specifically for HLA-A*02:01-positive unresectable or metastatic uveal melanoma.
The company also has substantial financial capacity to pursue that strategy. Immunocore ended September with approximately $512 million in cash and $389 million in marketable securities, or just over $900 million combined.
That balance sheet reduces near-term financing pressure around DUET-UVEAL and the company’s parallel Phase 3 programmes, although expanding a commercial and late-stage pipeline simultaneously will continue to require substantial development spending.
Why did Immunocore shares rise more than 9% after the November 6 updates?
Immunocore shares closed November 6 at $30.99, up 9.1% from $28.40 in the previous session, with trading volume rising to roughly 1.5 million shares. The stock remained within a 52-week range of approximately $27.50 to $40.72.
The move followed both the company’s third-quarter financial update and the release of the brenetafusp combination data, so attributing the entire gain to one announcement would overstate the evidence. Investors received several pieces of information on the same day, including KIMMTRAK sales, the company’s cash position, pipeline milestones and the new SITC dataset.
The combination data nonetheless address an important valuation question. Immunocore’s future cannot depend indefinitely on commercial expansion of KIMMTRAK in a relatively small genetically defined metastatic uveal melanoma population. The company needs additional indications and additional assets capable of validating its ImmTAC platform.
Brenetafusp now contributes to that argument through several independent routes: monotherapy activity, the KIMMTRAK combination signal and an ongoing Phase 3 cutaneous melanoma programme. The November data reduce some biological uncertainty around the candidate, but the programme remains exposed to substantial clinical-development risk.
Can two T-cell engagers become better than one without simply doubling treatment complexity?
That is the core question behind Immunocore’s next development stage.
The Phase 1/2 results contain several signals worth taking seriously. The first-line combination produced a 29% response rate, median response duration of 24.1 months and an estimated 70% two-year survival rate. Median overall survival remained unreached after 29 months, and no Grade 3 or Grade 4 cytokine release syndrome was reported with the combination.
Yet none of those findings establishes that brenetafusp improves upon KIMMTRAK. Seventeen evaluable first-line patients cannot provide the comparative evidence needed to change treatment practice, particularly when the existing therapy already has robust randomised survival data and five years of follow-up.
DUET-UVEAL therefore has an unusually clean scientific task. Immunocore does not need to show that T-cell redirection works in metastatic uveal melanoma. KIMMTRAK has already done that. It must show that directing T cells simultaneously against gp100 and PRAME produces enough additional clinical benefit to justify giving patients a second engager.
If the 70% two-year survival estimate holds up in a randomised trial, the significance would extend well beyond one rare melanoma subtype. It would provide some of the first controlled evidence that combining separate antigen-specific T-cell engagers can improve solid-tumour treatment rather than merely intensify immune activation. Until DUET-UVEAL produces that answer, the SITC data are a compelling hypothesis with unusually encouraging human support, not yet a new standard of care.
